Tiltan Pharma
CLINICAL PROGRAMS
Clinical Trials
Case Reports
Related Publications


 
Clinical Trials

Up to December 2009 a total of 80 patients received Hamsa-1. The patients were enrolled in 3 clinical studies and a compassionate use program. The total human exposure through December 2009 exceeded 24 patient years, with treatment duration ranging from 1 week to 3 years as summarized in the Table below:

 

Study Title
 
Study ID /
Status
Design
Enrolled subjects (N)
Treatment Formulation
Treatment Duration (weeks)
Hamsa-1
metastatic CRPC
Open-label single arm Assessment of product efficacy, safety and tolerability
24
Range: 1-23
Mean: 8
Median: 6
Study ongoing and enrolling
Hamsa-1
Solid Tumors
4237/2006
Completed
Open-label single arm
Assessment of product safety and preliminary efficacy
31
Range: 2-151
Mean: 21
Median: 12
Hamsa-1 Glioblastoma
07-208
Completed
Open-label single arm
Assessment of product safety and preliminary efficacy
11
Range: 1-13
Mean: 6.8
Median: 4
Hamsa-1
Solid Tumors
NA
 
Compassionate use (open label)
14
Range: 1-49
Mean: 20.4
Median: 13

Print Version Print Version       Send to a friend Send to a friend